

LORENZO DE PAOLI

CURRICULUM VITAE

ed

ELENCO DELLE PUBBLICAZIONI

Lorenzo De Paoli, MD, PhD

Struttura Complessa a Direzione Universitaria Ematologia
Dipartimento di Medicina Clinica e Sperimentale e
Università degli Studi del Piemonte Orientale Amedeo
Avogadro

Via Solaroli, 17
28100 Novara

E-mail: lorenzo.depaoli@med.uniupo.it

Novara, 16 gennaio 2017

CURRICULUM VITAE

Luogo e data di nascita: Novara, 10/01/1980

Formazione accademica

- 1999:** Diploma di maturità scientifica (100/100), Liceo Scientifico statale “A. Antonelli”, Novara
- 2003-05:** Allievo interno presso la U.D.A. Ematologia (Responsabile Prof. G. Gaidano), Clinica Medica Generale , Azienda Ospedaliera Maggiore della Carità, Novara
- 2005:** Laurea in Medicina e Chirurgia, Università del Piemonte Orientale A. Avogadro (110/110 lode). Materia: Ematologia. Titolo di tesi: “Identificazione di nuovi marcatori molecolari di prognosi nel Linfoma Diffuso a Grandi Cellule B” (Relatore: Prof. G. Gaidano)
- 2005-09:** Contrattista in Formazione – Specializzando, Scuola di Specializzazione in Ematologia, Università di Milano-Bicocca
- 2009:** Specializzazione in Ematologia presso Università degli Studi di Milano-Bicocca (70/70 con lode). Titolo di tesi: “Trasformazione da “Monoclonal B-cell lymphocytosis a leucemia linfatica cronica: identificazione di predittori clinici e biologici” (Relatore Prof. E.M. Pogliani).
- 2009-13:** Dottorando in Medicina Clinica e Sperimentale, Divisione di Ematologia, Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale A. Avogadro
- 2013:** Dottorato in Medicina Clinica e Sperimentale, Divisione di Ematologia, Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale A. Avogadro. Titolo di tesi: “ Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia” (Coordinatore Prof. M. Gariglio, Tutor Prof. G. Gaidano)

Borse di studio

- 2002-05:** Vincitore Borsa di studio Nobile Collegio Caccia
- 2007:** Vincitore Borsa di studio Novara-AIL Onlus / Fondazione Zegna

Esperienza clinica e professionale

- 2005-09:** Frequenza in qualità di Contrattista in Formazione presso la Struttura Complessa a Direzione Universitaria (S.C.D.U) Ematologia (Dir. Prof. G. Gaidano) della Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, svolgendo le seguenti attività: i) attività ambulatoriale e di Day Hospital per patologie oncoematologiche ed emoglobinopatie; ii) attività assistenziale in ambito di degenza ordinaria e di trapianto di cellule staminali emopoietiche autologhe; iii) gestione dei disordini dell'emostasi e della Terapia Anticoagulante Orale; iv) diagnostica morfologica citologica delle malattie del sangue

- 2009-14:** Dirigente Medico a tempo determinato presso la Struttura Complessa a Direzione Universitaria (S.C.D.U.) Ematologia (Dir. Prof. G. Gaidano) dell' Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
- 2015-** Dirigente medico a tempo indeterminato presso la Struttura Complessa a Direzione Universitaria (S.C.D.U.) Ematologia (Dir. Prof. G. Gaidano) dell' Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
- 2015-** Coordinatore GIC (gruppo interdisciplinare cura) delle neoplasie linfoidi, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
- 2015-** Referente per l'Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara della Rete Oncoematologica del Piemonte per il mieloma multiplo
- 2016** Docente presso la Scuola di Specialità di Radioterapia Università del Piemonte Orientale Amedeo Avogadro Novara per le neoplasie ematologiche

Appartenenza a Società Scientifiche e Gruppi di Ricerca di Società Scientifiche

- 2009-:** Società Italiana di Ematologia (SIE)
- 2010-:** Società Italiana di Citometria Clinica e Sperimentale (S.I.Ci.C.S.)

Seminari, relazioni e letture su invito

- *Expert Meeting ECHO "Leucemia Linfatica Cronica", relatore (Pollenzo, 28/05/2009)*
- *La compliance alla terapia chelante nella Talassemia, relatore (Torino, 16/04/2010).*
- *Progetto AVATAR (Zoledronic Acid Value and Anti Tumor Activity Round Tables). Presentazione di casi clinici e discussione interattiva (Torino, 05/11/2010)*
- *Piastrinopenie autoimmuni: nuove certezze terapeutiche e prospettive future, relatore (Torino, 10/12/2010)*
- *La gestione dell'ITP cronica: un anno dopo l'arrivo del primo TPO mimetico. Relatore (Torino, 16/12/2011)*
- *"Global Expert Forum on advance in B-Cell malignancies", relatore (Paris, 27 e 28/02/2015)*
- *"IGs day break: the advent of innovation", relatore (Roma, 28 and 29/05/2015)*
- *"Mieloma multiplo: il futuro è già qui -Save the date", relatore (Torino, 17/11/2015)*
- *"Nuove frontiere nella leucemia linfatica cronica", relatore (Torino 5/2/2016)*
- *XXXI corso di aggiornamento in Nefrologia e dialisi, "Monoclonal Gammopathy of Renal Significance (MGRS)", relatore (Torino, 10/05/2016)*
- *"Il valore dell'innovazione nella cura del mieloma multiplo", speaker (Milano 23/05/2016)*
- *"Mieloma multiplo, scenari in evoluzione", relatore (Torino 20/09/2016)*
- *" Le terapie target nella LLC: la gestione pratica in uno scenario terapeutico che cambia": relatore (8/11/2016)*
- *"Skyforum mieloma multiplo: nuovi scenari terapeutici": relatore (Pollenzo, 24/11/2016)*

Lingue straniere

- Inglese

PROSPETTO delle PUBBLICAZIONI

Bibliometria

Lavori su riviste internazionali con Impact Factor	34
Impact Factor cumulative (<i>I.F. secondo ISI 2011</i>)	231.7

Lavori su riviste internazionali senza Impact Factor	1
--	----------

Lavori su riviste internazionali con Impact Factor come collaboratore	4
---	----------

Lecture, relazioni, atti di Congressi Internazionali	2
--	----------

Lecture, relazioni, atti di Congressi Nazionali	6
---	----------

Abstract

Abstract su atti di Congressi Internazionali	29
--	-----------

Abstract su atti di Congressi Nazionali	28
---	-----------

PUBBLICAZIONI SCIENTIFICHE

Pubblicazioni in extenso con Impact Factor (I.F. secondo ISI 2011)

1. Rossi D, Cresta S, Destro T, Vendramin C, Bocchetta S, **De Paoli L**, Cerri M, Lunghi M, Gaidano G.
JAK2V617F IN IDIOPATHIC VENOUS THROMBOEMBOLISM OCCURRING IN THE ABSENCE OF INHERITED OR ACQUIRED THROMBOPHILIA.
Br J Haematol, 138:813-814, 2007 (*Lettera*)
IF: 4.941
2. Rossi D, **De Paoli L**, Franceschetti S, Capello D, Vendramin C, Lunghi M, Conconi A, Magnani C, Gaidano G.
PREVALENCE AND CLINICAL CHARACTERISTICS OF IMMUNE THROMBOCYTOPENIC PURPURA IN A COHORT OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE.
Br J Haematol, 138:249-252, 2007
IF: 4.941
3. Rossi D, Franceschetti S, Capello D, **De Paoli L**, Lunghi M, Conconi A, Gaidano G.
TRANSIENT MONOCLONAL EXPANSION OF CD8+/CD57+ T-CELL LARGE GRANULAR LYMPHOCYTES AFTER PRIMARY CYTOMEGALOVIRUS INFECTION.
Am J Hematol, 82:1103-1105, 2007
IF: 4.671
4. Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A, **De Paoli L**, Cresta S, Rasi S, Spina V, Franceschetti S, Lunghi M, Vendramin C, Bomben R, Ramponi A, Monga G, Conconi A, Magnani C, Gattei V, Gaidano G.
BIOLOGICAL AND CLINICAL RISK FACTORS OF CHRONIC LYMPHOCYTIC LEUKAEMIA TRANSFORMATION TO RICHTER'S SYNDROME.
Br J Haematol, 142:202-215, 2008
IF: 4.941
5. Rossi D, **De Paoli L**, Rossi FM, Cerri M, Deambrogi C, Rasi S, Zucchetto A, Capello D, Gattei V, Gaidano G.
EARLY STAGE CHRONIC LYMPHOCYTIC LEUKAEMIA CARRYING UNMUTATED IGHV GENES IS AT RISK OF RECURRENT INFECTIONS DURING WATCH AND WAIT.
Br J Haematol, 141:734-736, 2008 (*Lettera*)
IF: 4.941

6. Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C, Cresta S, Rasi S, **De Paoli L**, Lobetti Bodoni C, Bulian P, Del Poeta G, Ladetto M, Gattei V, Gaidano G.
CD49d EXPRESSION IS AN INDEPENDENT RISK FACTOR OF PROGRESSIVE DISEASE IN EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA.
Haematologica, 93:1575-1579, 2008
IF: 6.424

7. Deambrogi C, Cresta S, Cerri M, Rasi S, **De Paoli L**, Ramponi A, Gaidano G, Rossi D.
14q32 TRANSLOCATIONS AND RISK OF RICHTER'S TRANSFORMATION IN CHRONIC LYMPHOCYTIC LEUKAEMIA.
Br J Haematol, 144:131-133, 2009 (*Lettera*)
IF: 4.941

8. Lunghi M, Riccomagno P, **De Paoli L**, Vendramin C, Conconi A, Gaidano G, Rossi D.
MONITORING OF CYTOMEGALOVIRUS REACTIVATION DURING INDUCTION AND NONTRANSPLANT CONSOLIDATION OF ACUTE LEUKEMIA.
Am J Hematol, 84:697-698, 2009 (*Lettera*)
IF: 4.671

9. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, **De Paoli L**, Spina V, Gattei V, Capello D, Forconi F, Lauria F, Gaidano G.
THE PROGNOSTIC VALUE OF TP53 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA IS INDEPENDENT OF del17p13: IMPLICATIONS FOR OVERALL SURVIVAL AND CHEMOREFRACTORINESS.
Clin Cancer Res, 15:995-1004, 2009
IF: 7.742

10. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, Deambrogi C, Ricca I, Rocci A, Ferrero S, Bernocco E, Capello D, **De Paoli L**, Bergui L, Boi M, Omedè P, Massaia M, Tarella C, Passera R, Boccadoro M, Gaidano G, Ladetto M.
TELOMERE LENGTH IS AN INDEPENDENT PREDICTOR OF SURVIVAL, TREATMENT REQUIREMENT AND RICHTER'S SYNDROME TRANSFORMATION IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Leukemia, 23:1062-1072, 2009
IF: 9.561

11. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, **De Paoli L**, Ramponi A, Chiappella A, Pogliani EM, Vitolo U, Kwee I, Bertoni F, Conconi A, Gaidano G.
ANALYSIS OF THE HOST PHARMACOGENETIC BACKGROUND FOR PREDICTION OF OUTCOME AND TOXICITY IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP21.
Leukemia, 23:1118-1126, 2009
IF: 9.561

12. Rossi D, Sozzi E, Puma A, **De Paoli L**, Rasi S, Spina V, Gozzetti A, Tassi M, Cencini E, Raspadori D, Pinto V, Bertoni F, Gattei V, Lauria F, Gaidano G, Forconi F.
THE PROGNOSIS OF CLINICAL MONOCLONAL B CELL LYMPHOCYTOSIS DIFFERS FROM PROGNOSIS OF RAI 0 CHRONIC LYMPHOCYTIC LEUKAEMIA AND IS RECAPITULATED BY BIOLOGICAL RISK FACTORS.
Br J Haematol, 146:64-75, 2009
IF: 4.941

13. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, **De Paoli L**, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu JF, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri SA, Gattei V, Gaidano G.
STEREOTYPED B-CELL RECEPTOR IS AN INDEPENDENT RISK FACTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA TRANSFORMATION TO RICHTER SYNDROME.
Clin Cancer Res, 15:4415-4422, 2009
IF: 7.742

14. Deambrogi C, **De Paoli L**, Fangazio M, Cresta S, Rasi S, Spina V, Gattei V, Gaidano G, Rossi D.
ANALYSIS OF THE REL, BCL11A AND MYCN PROTO-ONCOGENES BELONGING TO THE 2p AMPLICON IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Am J Hematol, 85:541-544, 2010 (*Lettera*)
IF: 4.671

15. Lunghi M, Casorzo L, **De Paoli L**, Riccomagno P, Rossi D, Gaidano G.
DERIVATIVE (1)t(1;16)(p11;p11.1) IN MYELOYDYSPLASTIC SYNDROME: A CASE REPORT AND REVIEW OF THE LITERATURE.
Cancer Genet Cytogenet, 196:89-92, 2010
IF: 1.389

16. Rossi D, Deambrogi C, Monti S, Cresta S, **De Paoli L**, Fangazio M, Giardini I, Brnasconi P, Gaidano G.
BCL3 TRANSLOCATION IN CLL WITH TYPICAL PHENOTYPE: ASSESMENT OF FREQUENCY, ASSOCIATION WITH CYTOGENETIC SUBGROUPS, AND PROGNOSTIC SIGNIFICANCE.
Br J Haematol, 150:702-704, 2010 (*Lettera*)
IF: 4.941

17. Rossi D, Fangazio M, **De Paoli L**, Puma A, Riccomagno P, Pinto V, Zigrossi P, Ramponi A, Monga G, Gaidano G.
BETA-2-MICROGLOBULIN IS AN INDEPENDENT PREDICTOR OF PROGRESSION IN ASYMPTOMATIC MULTIPLE MYELOMA.
Cancer, 116:2188-2200, 2010
IF: 4.771

18. Rossi D, Lobetti Bodoni C, Zucchetto A, Rasi S, **De Paoli L**, Fangazio M, Rossi FM, Ladetto M, Gattei V, Gaidano G.
LOW CD49d EXPRESSION AND LONG TELOMERE IDENTIFY A CHRONIC LYMPHOCYTIC LEUKEMIA SUBSET WITH HIGHLY FAVOURABLE OUTCOME.
Am J Hematol, 85:619-622, 2010 (*Lettera*)
IF: 4.671

19. Fangazio M*, **De Paoli L***, Rossi D, Gaidano G.

PREDICTIVE MARKERS AND DRIVING FACTORS BEHIND RICHTER SYNDROME DEVELOPMENT.

Expert Rev Anticancer Ther, 11:433-442, 2011 (* equal contribution)

IF: 2.652

20. Rasi S, Bruscaggin A, Rinaldi A, Cresta S, Fangazio M, **De Paoli L**, Monti S, Gargiulo E, Kwee I, Foà R, Bertoni F, Gaidano G, Rossi D.
SALIVA IS A RELIABLE AND PRACTICAL SOURCE OF GERMLINE DNA FOR GENOME-WIDE STUDIES IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Leuk Res, 35:1419-1422, 2011
IF: 2.923
21. Rasi S, Spina V, Bruscaggin A, Vaisitti T, Tripodo C, Forconi F, **De Paoli L**, Fangazio M, Sozzi E, Cencini E, Laurenti L, Marasca R, Visco C, Xu-Monette ZY, Gattei V, Young KH, Malavasi F, Deaglio S, Gaidano G, Rossi D.
A VARIANT OF THE LRP4 GENE AFFECTS THE RISK OF CHRONIC LYMPHOCYTIC LEUKAEMIA TRANSFORMATION TO RICHTER SYNDROME.
Br J Haematol, 152:284-294, 2011
IF: 4.941
22. Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F, Gloghini A, Bruscaggin A, Franceschetti S, Fangazio M, **De Paoli L**, Bruna R, Capello D, Chiappella A, Lobetti Bodoni C, Giachelia M, Tisi MC, Pogliani EM, Lauria F, Ladetto M, Hohaus S, Martelli M, Vitolo U, Carbone A, Foà R, Gaidano G.
THE HOST GENETIC BACKGROUND OF DNA REPAIR MECHANISMS IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA.
Blood, 117:2405-2413, 2011
IF: 9.898
23. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti R, Bruscaggin A, Cerri M, Monti S, Cresta S, Famà R, **De Paoli L**, Bulian P, Gattei V, Guarini A, Deraglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Foà R, Gaidano G.
MUTATIONS OF NOTCH1 ARE AN INDEPENDENT PREDICTOR OF SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Blood, 119:521-529, 2012
IF 9.898
24. Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A, Grasso M, Siez ML, **De Paoli L**, Oliva S, Molica S, Mina R, Gay F, Benevolo G, Musto P, Omedè P, Freilone R, Bringhen S, Carella AM, Gaidano G, Boccadoro M, Palumbo A.
LENALIDOMIDE-PREDNISONE INDUCTION FOLLOWED BY LENALIDOMIDE-MELPHALAN-PREDISONE CONSOLIDATION AND LENALIDOMIDE-PREDNISONE MAINTENANCE IN NEWLY DIAGNOSED ELDERLY UNFIT MYELOMA PATIENTS.
Leukemia, 27 (3): 695-701, 2013
IF 9.561

25. **De Paoli L**, Cerri M, Monti S, Rasi S, Spina V, Bruscaggin A, Greco M, Ciardullo C, Famà R, Cresta S, Maffei R, Ladetto M, Martini M, Laurenti L, Forconi F, Marasca R, Larocca LM, Berton F, Gaidano G, Rossi D.
MGA, A SUPPRESSOR OF MYC, IS RECURRENTLY INACTIVATED IN HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA.
Leuk Lymphoma, 54 (5): 1087-90, 2013
IF 2.580

26. Montillo M, Tedeschi A, Gaidano G, Coscia M, Belsito Petrizzi V, Orlandi E, Cascavilla N, Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, **De Paoli L**, Nichelatti M, Morra E, Massaia M.
BENDAMUSTINE AND SUBCUTANEOUS ALEMTUZUMAB COMBINATION IS AN EFFECTIVE TREATMENT IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.
Haematologica, pii: haematol.2014.106740
IF: 6.424

27. Rossi D, Khiabani H, Spina V, Ciardullo C, Bruscaggin A, Famà R, Rasi S, Monti S, Deambrogi C, **De Paoli L**, Wang J, Gattei V, Guarini A, Foà R, Rabadan R, Gaidano G.
CLINICAL IMPACT OF SMALL TP53 MUTATED SUBCLONES IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Blood, 123:2139-47, 2014
IF 9.898

28. Peretti A, Borgogna C, Rossi D, **De Paoli L**, Bawadekar M, Zavattaro E, Boldorini R, De Andrea M, Gaidano G, Gariglio M.
ANALYSIS OF HUMAN BETA PAPILLOMAVIRUS AND MERKEL CELL POLYOMAVIRUS INFECTION IN SKIN LESIONS AND EYEBROW HAIR BULBS FROM A COHORT OF CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS.
Br J Dermatol, 2014, doi 10.1111/bjd. 13215
IF 3.759

29. Rossi D, Terzi-di-Bergamo L, **De Paoli L**, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G.
MOLECULAR PREDICTION OF DURABLE REMISSION AFTER FIRST LINE FLUDARABINE-CYCLOPHOSPHAMIDE-RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA
Blood, 2015, pii: blood-2015-05-647925
IF 9.898

30. Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, **De Paoli L**, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M; Rete Ematologica Lombarda (REL)–CLL workgroup.
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.
Haematologica, 2015, doi: 10.3324/haematol.2015.132035. Epub 2015 Aug 20
IF 6.424

31. Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, **De Paoli L**, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A.
TRIPLET VS DOUBLET LENALIDOMIDE-CONTAINING REGIMENS FOR THE TREATMENT OF ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.
Blood, 2016 pii: blood-2015-08-662627
IF 9.898

32. Rasi S, Khiabani H, Ciardullo C, Terzi-di-Bergamo L, Monti S, Spina V, Bruscaggin A, Cerri M, Deambrogi C, Martuscelli L, Biasi A, Spaccarotella E, **De Paoli L**, Gattei V, Foa R, Rabadan R, Gaidano G, Rossi D.
CLINICAL IMPACT OF SMALL SUBCLONES HARBORING NOTCH1, SF3B1 OR BIRC3 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Haematologica, 2016 Jan 27. pii: haematol.2015.136051
IF 6.424

33. Larocca A, Bringhen S, Teresa Petrucci M, Oliva S, Pia Falcone A, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Montefusco V, Passera R, De Rosa L, Omedé P, Vincelli ID, Spada S, Carella AM, Ponticelli E, Derudas D, Genuardi M, Guglielmelli T, Nozzoli C, Aghemo E, **De Paoli L**, Conticello C, Musolino C, Offidani M, Boccadoro M, Sonneveld P, Palumbo A
A PHASE 2 STUDY OF THREE LOW-DOES INTENSITY SUBCUTANEOUS BORTEZOMIB REGIMENS IN ELDERLY FRAIL PATIENTS WITH UNTREATED MULTIPLE MYELOMA
Leukemia, 2016 Feb 22. doi: 10.1038/leu.2016.36.
IF 9.561

34. **De Paoli L**, Gaidano G.
CHRONIC LYMPHOCYTIC LEUKAEMIA: A STEP AHEAD IN THE JOURNEY TOWARD ERADICATION
Lancet Oncology, 2017 Jan doi: 10.1016/S1470-2045(17)30017-7
IF 26.509

Pubblicazioni in extenso senza Impact Factor

35. Ripellino P, Comi C, Mula M, Varrasi C, Conconi A, Stecco A, Brustia D, Nasuelli N, Savio K, **De Paoli L**, Cantello R, Gaidano G, Monaco F.
PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHY AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION: A TREATMENT OPTION.
BMJ Case Reports doi:10.1136/bcr.11.2010.3549, 2011.

Pubblicazioni in extenso con Impact Factor come collaboratore

36. Knoebl P, Marco P, Baudo F, Collins P, Huth-Kuhne A, Nemes L, Pellegrini F, Tengborn L, Lévesque H; **EACH2 Registry Contributors**. DEMOGRAPHIC AND CLINICAL DATA IN ACQUIRED HEMOPHILIA A: RESULTS FROM THE EUROPEAN ACQUIRED HAEMOPHILIA REGISTRY (EACH2).
J Thromb Haemost 10 (4): 622-31, 2012
37. Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pellegrini F, Marco P, Tengborn L, Huth-Kuhne A; **EACH2 Registry Contributors**. IMMUNOSUPPRESSION FOR ACQUIRED HEMOPHILIA: RESULTS FROM THE EUROPEAN ACQUIRED HAEMOPHILIA REGISTRY (EACH2)
Blood, 120 (1): 47-55, 2012
38. Baudo F, Collins P, Huth-Kuhne A, Knoebl P, Lévesque H, Marco P, Nemes L, Pellegrini F, Tengborn L, Knoebl P; **EACH2 Registry Contributors**. MANAGEMENT OF BLEEDING IN ACQUIRED HEMOPHILIA A: RESULTS FROM THE EUROPEAN ACQUIRED HAEMOPHILIA (EACH2)
Blood, 120 (1): 39-46, 2012
39. Tengborn L, Baudo F, Huth-Kuhne a, Lévesque H, Marco P, Pellegrini F, Nemes L, Collins P; **EACH2 Registry Contributors**. PREGNANCY – ASSOCIATED ACQUIRED HAEMOPHILIA A: RESULTS FROM THE EUROPEAN ACQUIRED HAEMOPHILIA (EACH2)
BJOG, 119 (12): 1529-37, 2012

Atti di congressi internazionali

40. Rossi D, Franceschetti S, Vendramin C, Manfroi F, **De Paoli L**, Benevolo G, Gaidano G.
IMMUNODEFICIENCY AND LYMPHOMA: FROM AIDS TO POST-TRANSPLANT.
Haematologica 88-s10: 7-8, 2003
41. Gaidano G, Rossi D, Cerri M, Franceschetti S, Berra E, Deambrogi C, Vigano F, Cortina F,
De Paoli L, Conconi A, Capello D.
MOLECULAR HISTOGENESIS AND PATHOGENESIS OF HIV-RELATED
LYMPHOMA.
Haematologica 90-s1: 389-391, 2005

Atti di Congressi nazionali

42. Franceschetti S, Deambrogi C, Cerri M, Riccomagno P, Cresta S, **De Paoli L**, Ramponi A,
Rossi D, Conconi A, capello D, Gaidano G.
DIAGNOSI MOLECOLARE DEI LINFOMI: IMPLICAZIONI CLINICHE.
In Collegio Ghislieri – Centro per la Comunicazione e la Ricerca – Progetto “Progressi in
Biologia e Medicina” – 7° Corso di formazione avanzata “Nanomedicina: dalle
nanostrutture alla terapia personalizzata”. Pavia: Edimes, 2008, pp. 114-120.
43. Rasi S, Franceschetti S, Bruscaggin A, Spina V, Bruna R, Riccomagno P, **De Paoli L**, Rossi
D, Gaidano G.
ALTERAZIONI GENETICHE E INTERAZIONI CON IL MICROAMBIENTE NEI
LINFOMI MALIGNI.
In Collegio Ghislieri – Centro per la Comunicazione e la Ricerca – Progetto “Progressi in
Biologia e Medicina” – 9° Corso di formazione avanzata “Cellule staminali tumorali: il vero
bersaglio nella cura dei tumori”. Pavia: Edimes, 2010, pp. 140-144.
44. Spina V, Rasi S, Bruscaggin A, Fangazio M, Deambrogi C, Monti S, Cresta S, Famà R,
Greco M, Ciardullo C, Piranda D, **De Paoli L**, Rossi D, Gaidano G.
BIOLOGICAL AND CLINICAL PREDICTORS OF CHRONIC LYMPHOCYTIC
LEUKEMIA TRANSFORMATION TO RICHTER SYNDROME.
In Collegio Ghislieri – Centro per la Comunicazione e la Ricerca – Progetto “Progressi in
Biologia e Medicina” – 11° Corso di formazione avanzata “Medicina genomica e terapia
personalizzata in ematologia/oncologia”. Pavia: Edimes, 2012, pp. 117-130.
45. **De Paoli L**.
Conference insight. IGs Daybreak. The advent of innovation.
L’avvento delle SCIG facilitate in Italia: prime esperienze nel trattamento delle SID
Roma, 28-29 maggio 2015, pp 30-34

Abstract di Congressi internazionali

1. Rossi D, Deambrogi C, Lunghi M, Cerri M, Garbellotto S, Spina V, **De Paoli L**, Riccomagno P, Gloghini A, Lucioni M, Capello D, Paulli M, Carbone A, Gaidano G. ABERRANT METHYLATION OF SHP-1 (SH2-CONTAINING PHOSPHATASE 1) AND SOCS-1 (SUPPRESSOR OF CYTOKINE SIGNALLING 1) GENES IN IMMUNODEFICIENCY-RELATED LYMPHOMAS. *Blood* 108: 675a, 2006
2. Rossi D, Deambrogi C, Capello D, Cerri M, Lunghi M, **De Paoli L**, Parvis G, Saglio G, Gaidano G, Cilloni D. JAK2V617F MUTATION IN LEUKAEMIC TRANSFORMATION OF PHILADELPHIA NEGATIVE CHRONIC MYELOPROLIFERATIVE DISORDERS. *Blood* 108: 1030a, 2006
3. Cerri M, Deambrogi C, Rossi D, Lunghi M, Zigrossi P, Spina V, **De Paoli L**, Riccomagno P, Gloghini A, Lucioni M, Capello D, Paulli M, Carbone A, Gaidano G. ABERRANT METHYLATION OF SHP-1 (SH2-CONTAINING PHOSPHATASE-1) AND SOCS-1 (SUPPRESSOR OF CYTOKINE SIGNALING-1) GENES IN IMMUNODEFICIENCY-RELATED LYMPHOMAS. *Haematologica/Hematol J* 92 (s1): 105, 2007
4. Rossi D, **De Paoli L**, Franceschetti S, Capello D, Vendramin C, Lunghi M, Conconi A, Magnani C, Gaidano G. INCIDENCE AND CLINICAL CHARACTERISTICS OF IMMUNE THROMBOCYTOPENIC PURPURA IN A COHORT OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE. *Haematologica/Hematol J* 92 (s1): 401, 2007
5. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, Chiappella A, **De Paoli L**, Ramponi A, Pogliani E, Vitolo U, Conconi A, Gaidano G. THE HOST PHARMACOGENETIC PROFILE IS AN INDEPENDENT PREDICTOR OF OUTCOME AND TOXICITY IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP21. *Haematologica/Hematol J* 93 (s1): 159, 2008
6. Rossi D, Lobetti Bodoni C, Genuardi E, Montillo L, Cerri M, Deambrogi C, Drandi D, Ricca I, Rocci A, Boi M, Ferrero S, Capello D, **De Paoli L**, Bergui L, Omedè P, Massaia M, Boccadoro M, Gaidano G, Ladetto M. SHORT TELOMERE LENGTH IS AN INDEPENDENT PREDICTOR OF SURVIVAL, PROGRESSION, RICHTER'S SYNDROME TRANSFORMATION AND RECURRENT INFECTIONS: AN ANALYSIS ON 421 CLL PATIENTS INCLUDING BLINDED VALIDATION ON 230 CASES. *Haematologica/Hematol J* 93 (s1): 162-163, 2008
7. Rossi D, Zucchetto A, Rossi FM, Capello D, cerri M, Deambrogi C, Cresta S, Rasi S, **De Paoli L**, Lobetti Bodoni C, Bulian P, Del Poeta G, Ladetto M, Gattei V, Gaidano G. CD49d EXPRESSION IS AN INDEPENDENT RISK FACTOR OF PROGRESSIVE DISEASE IN EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/Hematol J* 93 (s1): 163, 2008
8. Cerri M, Deambrogi C, Capello D, Cresta S, Rasi S, Sozzi E, **De Paoli L**, Gattei V, Forconi F; gaidano G, Rossi D. TP53 MUTATIONS AND del17p13 PREDICT SIMILAR OUTCOME AND CHEMOREFRACTORINESS IN CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/Hematol J* 93 (s1): 163-164, 2008
9. Rossi D, Lobetti Bodoni C, Genuardi E, Montillo L, Drandi D, Deambrogi C, Cerri M,

- Ricca i, Rocci A, Ferrero S, Bernocco E, Capello D, **De Paoli L**, Bergui L, Boi M, Omede P, Massaia M, Tarella C, Passera R, Boccadoro M, Gaidano G. TELOMERE LENGTH IS AN INDEPENDENT PREDICTOR OF SURVIVAL, TREATMENT REQUIREMENT, AND RICHTER'S SYNDROME TRANSFORMATION IN CHRONIC LYMPHOCYTIC LEUKEMIA. *Blood* 112: 1052, 2008
10. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, **De Paoli L**, Ramponi A, Chiappella A, Pogliani E. M, Vitolo U, Kwee I, Bretoni F, Conconi A, Gaidano G. THE PHARMACOGENETIC BACKGROUND OF THE HOST IS AN INDEPENDENT PREDICTOR OF OUTCOME AND TOXICITY IN DIFFUSE LARGE B CELL LYMPHOMA TREATED WITH R-CHOP 21. *Blood* 112: 480, 2008
 11. Rossi D, Spina V, Cerri M, Deambrogi C, **De Paoli L**, Laurenti L, Maffei R, Forconi F, Canzonieru V, Bertoni F, Martini M, Rasi S, Magni M, Deaglio S, Ladetto M, Cabras A, Nomdedeu J, Besson C, Marasca R, Larocca L, Gattei V, Gaidano G. USAGE OF IGHV4-39 STEREOTYPIC B CELL RECEPTOR IS AN INDEPENDENT RSK FACTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA TRANSFORMATION TO RICHTER SYNDROME. *Blood* 112: 778, 2008
 12. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, **De Paoli L**, Capello D, Gattei V, Forconi F, Lauria F, Gaidano G. THE PROGNOSTIC VALUE OF TP53 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IS INDEPENDENT OF DEL17P13: IMPLICATIONS FOR OVERALL SURVIVAL AND CHEMOREFRACTORINESS. *Blood* 112: 3137, 2008
 13. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, **De Paoli L**, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu JF, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri S, Gattei V, Gaidano G. STEROTYPED B CELL RECEPTOR AND IGHV4-39 USAGE REPRESENT INDEPENDENT RISK FACTORS OF CHRONIC LYMPHOCYTIC LEUKEMIA TRANSFORMATION TO RICHTER SYNDROME. *Haematologica/The Hematology Journal* 94(s2): 139, 2009
 14. Rossi D, Fangazio M, **De Paoli L**, Pinto V, Riccomagno P, Puma A, Ramponi A, Gaidano G. BETA2MICROGLOBULIN IS AN INDEPENDENT PREDICTOR OF PROGRESSION IN ASYMPTOMATIC MULTIPLE MYELOMA. *Haematologica/The Hematology Journal* 94(s2): 156, 2009
 15. Forconi F, Puma A, **De Paoli L**, Rasi S, Spina V, Gozzetti A, Tassi M, Sozzi E, Cencini E, Raspadori D, Bertoni F, Gattei V, Lauria F, Gaidano G, Rossi D. THE PROGNOSIS OF CLINICAL MONOCLONAL B CELL LYMPHOCYTOSIS DIFFERS FROM PROGNOSIS OF RAI 0 CHRONIC LYMPHOCYTIC LEUKEMIA AND IS RECAPITUALTED BY BIOLOGICAL RISK FACTORS. *Haematologica/The Hematology Journal* 94(s2): 370, 2009
 16. Rossi D, Rasi S, Fabbri A, Forconi F, Fangazio M, Bruscaaggini A, Franceschetti S, **De Paoli L**, Puma A, Bruna R, Chiappella A, Pogliani EM, Lauria F, Vitolo U, Gaidano G. THE HOST GENETIC BACKGROUND OF DNA REPAIR MECHANISMS REPRESENTS AN INDEPENDENT PREDICTOR OF PROGRESSION AND SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP. *Blood* 114: 442, 2009

17. Rossi D, Fangazio M, **De Paoli L**, Pinto V, Riccomagno P, Puma A, Ramponi A, Monga G, Gaidano G. BETA-2-MICROGLOBULIN IS AN INDEPENDENT PREDICTOR OF PROGRESSION IN ASYMPTOMATIC MULTIPLE MYELOMA. *Blood* 114: 1796, 2009
18. Gozzetti A, Oliva S, Gentilini F, Marchini E, Petrucci MT, Patriarca F, Petrucci A, Giaccone L, Zamagni E, Genuardi M, Cavo M, Palumbo A, Rossi D, Offidani M, Cerase A, **De Paoli L**, Florida M, Mele G, Galli M, Beretta S, Di Raimondo F, Vallone R, Lauria F. CENTRAL NERVOUS SYSTEM AND INTRACRANIAL MYELOMA: A RETROSPECTIVE ITALIAN MULTICENTER STUDY. *Blood* 114: 1882, 2009
19. Rossi D, Rasi S, Fabbri A, Forconi F, Bruscaggin A, Di Rocco A, Fangazio M, Franceschetti S, **De Paoli L**, Bruna R, Chiappella A, Pogliani E, Lauria F, Vitolo U, Hohaus S, Martelli M, Foà R, Gaidano G. A GENETIC VARIANT OF MLH1, A GENE INVOLVED IN DNA MISMATCH REPAIR, IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP. *Haematologica/Hematol J* 95 (s2): 237, 2010
20. Palumbo A, Falco P, Benevolo G, Rossi D, Carella AM, Guglielmelli T, Rocci A, **De Paoli L**, Grasso M, Mosca Siez ML, Piro E, Caltagirone S, Gay F, Cavallo F, Gaidano G, Boccadoro M. A MULTICENTER, OPEN LABEL STUDY OF ORAL LENALIDOMIDE AND PREDNISONE (RP) FOLLOWED BY ORAL LENALIDOMIDE MELPHALAN AND PREDNISONE (MPR) AND ORAL LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS. *Blood* 116: 1940, 2010
21. Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F, Bruscaggin A, Franceschetti S, Fangazio M, **De Paoli L**, Bruna R, Capello D, Chiappella A, Lobetti Bodoni C, Giachelia M, Tisi MC, Pogliani EM, Lauria F, Ladetto M, Hohaus S, Martelli M, Vitolo U, Foà R, Gaidano G. THE GENOTYPE OF MLH1 IS AN INDEPENDENT PREDICTOR OF OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP: A TRAINING-VALIDATION STUDY. *Blood* 116: 992, 2010
22. Bringhen S, Falco P, Rossi D, Guglielmelli T, Rocci A, **De Paoli L**, Grasso M, Benevolo G, Mosca Siez ML, Piro E, Ruggeri M, Palladino C, Genuardi M, Carella A, Gaidano G, Boccadoro M, Palumbo A. A MULTICENTER, OPEN LABEL STUDY OF LENALIDOMIDE AND PREDNISONE (RP) FOLLOWED BY LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS. *Haematologica/Hematol J* 96 (s2): 121, 2011
23. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscaggin A, Cerri M, Monti S, Cresta S, Famà R, **De Paoli L**, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Foà R, Gaidano G. MUTATIONS OF NOTCH1 ARE AN INDEPENDENT PREDICTOR OF SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA. *Blood* 118: 283, 2011
24. Tedeschi A, Rossi D, Coscia M, Vismara E, Belsito Petrizzi V, Orlandi E, Cascavilla N, Scarfò L, Motta M, Vitale C, Ricci F, **De Paoli L**, D'Arco AM, Gallamini A, Gaidano G, Morra E, Massaia M, Montillo M. FINAL REPORT OF BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. *Blood* 120: 2898, 2012

25. Zallio F, Baraldi A, Montefusco V, Cavallo F, **De Paoli L**, Minetto P, Catania G, Rapetti M, Gaidano G, salvi F, Levis A. SUCCESSFUL STEM CELL RE-MOBILIZATION AND HARVEST IN PATIENTS WITH MULTIPLE MYELOMA RELAPSED AFTER A PREVIOUS MYELOABLATIVE AUTOLOGOUS TRANSPLANT. *Haematologica/Hematol J* 98 (s1): 188, 2013
26. Bringhen S, Cerrato C, Petrucci MT, Genuardi M, Gentilini F, Conticello C, Oliva S, Pantani L, Offidani M, Palladino C, Benevolo G, Montefusco V, Astolfi M, Villani O, Siniscalchi A, Rocci A, **De Paoli L**, Boccadoro M, Sonneveld P, Palumbo A. A PHASE II STUDY WITH CARFILZOMIB , CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCd) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA. *Blood* 122: 685, 2013
27. Montillo M, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortellezzi A, Nador G, Scarfò L, Cairoli R, Dal Ceggio D, **De Paoli L**, Morra E, Rambaldi A, Orlandi E, Massaia M, Tedeschi A. A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS. *Blood* 122: 4177, 2013
28. Cerrato C, Oliva S, Petrucci MT, Caraffa P, Bozzoli C, Finsinger P, Larocca A, De Rosa L, **De Paoli L**, Montefusco V, Saraci E, Villani O, Carella AM, Benevolo G, Morabito F, Liberati AM, Derudas D, Boccadoro M, Sonneveld P, Palumbo A. EFFICACY AND SAFETY OF THREE SUBCUTANEOUS BORTEZOMIB COMBINATIONS IN ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. *Haematologica/Hematol J* 99 (s1): 4252, 2014
29. Montillo M, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortellezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dal Ceggio D, Picardi P, **De Paoli L**, Orlandi E, Rambaldi A, Morra E, Massaia M, Tedeschi A. A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS. *Haematologica/Hematol J* 99 (s1): 4238, 2014

Abstract di Congressi nazionali

30. Deambrogi C, Barbieri C, Cerri M, Garbellotto S, Spina V, **De Paoli L**, Rossi D, Gloghini A, Lucioni M, Capello D, Paulli M, Carbone A, Gaidano G, Lunghi M. ABERRANT METHYLATION OF SOCS-1 (SUPPRESSOR OF CYTOKINE SIGNALING-1) AND SHP-1 (SH2-CONTAINING PHOSPHATASE-1) GENES IN IMMUNODEFICIENCY-RELATED LYMPHOMAS. *Haematologica/The Hematology Journal* 91 (Suppl. 3): 41, 2006
31. Rossi D, Berra E, Cerri M, Deambrogi C, Barbieri C, Franceschetti S, Conconi A, **De Paoli L**, Paulli M, Matolcsy A, Pasqualucci L, Capello D, Gaidano G. ABERRANT SOMATIC HYPERMUTATION IS INVOLVED IN TRANSFORMATION OF FOLLICULAR LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA TO DIFFUSE LARGE B-CELL LYMPHOMA. *Haematologica/The Hematology Journal* 91 (Suppl. 3): 47, 2006

32. Rossi F, Marcheselli L, Rossi D, Callea V, Guffanti A, Federico V, De Muro M, Baraldi A, Musto P, Bacigalupo A, Gaidano G, Petrucci MT, Goldaniga M, **De Paoli L**, Baldini L. LOW RISK IgG MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS): PROPOSAL AND VALIDATION OF A PROGNOSTIC SCORING SYSTEM. *Haematologica/The Hematology Journal* 92 (Suppl. 3): 135, 2007
33. Rossi D, Deambrogi C, Cerri M, **De Paoli L**, Franceschetti S, Capello D, Vendramin C, Lunghi M, Conconi A, Gaidano G. LE LESIONI MOLECOLARI DEI GENI SHP-1, SOCS-1 E SOCS-3 RAPPRESENTANO UN MECCANISMO PATOGENETICO FREQUENTE NELLE MALATTIE MIELOPROLIFERATIVE CRONICHE PHIOADELPHIA NEGATIVE. *Internal and Emergency Medicine* 2: S9, 2007
34. Rossi D, **De Paoli L**, Cerri M, Deambrogi C, Vendramin C, Franceschetti S, Lunghi M, Conconi A, Capello D, Ramponi A, Gaidano G. VARIABILI CLINICO-BIOLOGICHE PREDITTIVE DI TRASFORMAZIONE DA LEUCEMIA LINFATICA CRONICA A LINFOMA DIFFUSO A GRANDI CELLULE B (SINDROME DI RICHTER). *Internal and Emergency Medicine* 2: S10-S11, 2007
35. Rossi D, **De Paoli L**, Franceschetti S, Capello D, Vendramin C, Lunghi M, Conconi A, Magnani C, Gaidano G. PREVALENZA E CARATTERISTICHE CLINICHE DELLA PORPORA TROMBOCITOPENICA IMMUNOLOGICA ASSOCIATA A GAMMOPATIA MONOCLONALE DI SIGNIFICATO INDETERMINATO (MGUS). *Internal and Emergency Medicine* 2: S48-S49, 2007
36. Rasi S, Rossi D, Franceschetti S, Capello D, Castelli A, Chiappella A, **De Paoli L**, Ramponi A, Pogliani E, Vitolo U, Conconi A, Gaidano G. THE PHARMACOGENETIC BACKGROUND OF THE HOST IS AN IDNEPENDENT PREDICTOR OF OUTCOME AND TOXICITY IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP21. *Haematologica/The Hematology Journal* 93 (Suppl. 2): 32, 2008
37. Rossi D, Cerri M, Forconi F, Deambrogi C, Sozzi E, Cresta S, Rasi S, Tassi M, **De Paoli L**, Raspadori D, Capello D, Gattei V, Lauria F, Gaidano G. TP53 MUTATIONS AND del17p13 PREDICT SIMILAR OUTCOME AND CHEMOREFRACTORINESS IN CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/The Hematology Journal* 93 (Suppl. 2): 91-92, 2008
38. Rossi D, Lobetti Bodoni C, Genuardi E, Montillo L, Cerri M, Deambrogi C, Drandi D, Ricca I, Rocci A, Boi M, Ferrero S, Capello D, **De Paoli L**, Bergui L, Omedè P, Massaia M, Boccadoro M, Gaidano G, Ladetto M. SHORT TELOMERE LENGTH IS AN INDEPENDENT PREDICTOR OF SURVIVAL, PROGRESSION, RICHTER'S SYNDROME TRANSFORMATION AND RECURRENT INFECTIONS: AN ANALYSIS ON 421 CLL PATIENTS INCLUDING BLINDED VALIDATION ON 230 CASES. *Haematologica/The Hematology Journal* 93 (Suppl. 2): 92, 2008
39. Deambrogi C, Cresta S, Cerri M, **De Paoli L**, Capello D, Gaidano G, Rossi D. BCL3 TRANSLOCATION IS A FREQUENT AND SELECTIVE EVENT IN CHRONIC LYMPHOCYTIC LEUKEMIA CARRYING +12. *Haematologica/The Hematology Journal* 93 (Suppl. 2): 92, 2008
40. Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C, Cresta S, Rasi S, **De Paoli L**, Lobetti Bodoni C, Bulian P, Del Poeta G, Ladetto M, Gattei V, Gaidano G. CD49d

EXPRESSION IS AN INDEPENDENT PREDICTOR OF PROGRESSIVE DISEASE IN BINET A CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/The Hematology Journal* 93 (Suppl. 2): 93, 2008

41. Rossi D, Cerri M, Deambrogi C, Capello D, Cresta S, Rasi S, Sozzi E, **De Paoli L**, Gattei V, Forconi F, Lauria F, Gaidano G. IL SIGNIFICATO PROGNOSTICO DELLE MUTAZIONI DI TP53 NELLA LEUCEMIA LINFATICA CRONICA E' INDIPENDENTE DALLA DELEZIONE 17p13: IMPLICAZIONI PER LA PROGNOSE E LA CHEMIOREFRATTARIETA' DELLA MALATTIA. *Internal and Emergency Medicine*, 3: S19-S20, 2008
42. Franceschetti S, Rossi D, Rasi S, Capello D, Castelli A, Chiappella A, **De Paoli L**, Ramponi A, Pogliani E, Vitolo U, Conconi A, Gaidano G. IL PROFILO FARMACOGENETICO DELL'OSPITE E' UN PREDITTORE INDIPENDENTE DI OUTCOME E DI TOSSICITA' NEL LINFOMA DIFFUSO A GRANDI CELLULE B TRATTATO CON R-CHOP21. *Internal and Emergency Medicine*, 3: S20, 2008
43. Rossi D, Zucchetto A, Rossi FM, Capello D, Cerri M, Deambrogi C, Cresta S, Rasi S, **De Paoli L**, Lobetti Bodoni C, Bulian P, Del Poeta G, Ladetto M, Gattei V, Gaidano G. L'ESPRESSIONE DI CD49d E' UN PREDITTORE INDIPENDENTE DI PROGRESSIONE DI MALATTIA NELLA LEUCEMIA LINFATICA CRONICA IN STADIO BINET A. *Internal and Emergency Medicine*, 3: S21, 2008
44. Rossi D, Lobetti Bodoni C, Genuardi E, Montillo L, Cerri M, Deambrogi C, Drandi D, Ricca I, Rocci A, Capello D, **De Paoli L**, Bergui L, Omedè P, Massaia M, Boccadoro M, Ladetto M, Gaidano G. LA LUNGHEZZA DEL TELOMERO E' UN FATTORE DI RISCHIO INDIPENDENTE DI MORTE, PROGRESSIONE E TRASFORMAZIONE A SINDROME DI RICHTER: ANALISI SU 401 CASI DI LEUCEMIA LINFATICA CRONICA. *Internal and Emergency Medicine*, 3: S25-26, 2008
45. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, **De Paoli L**, Laurenti I, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Ludioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu J.F, Besson C, Canzonieri V, Palli M, Marasca R, Larocca L.M, Carbone A, Pileri S.A, Gattei V, Gaidano G. STEROTYPIC B-CELL RECEPTOR AND IGHV4-39 USAGE REPRESENT INDEPENDENT RISK FACTORS OF CHRONIC LYMPHOCYTIC TRANSFORMATION TO RICHTER SYNDROME. *Haematologica/The Hematology Journal* 94 (Suppl. 4): 30, 2009
46. Fangazio M, **De Paoli L**, Pinto V, Riccomagno P, Puma A, Ramponi A, Gaidano G, Rossi D. BETA-2 MICROGLOBULIN IS AN INDEPENDENT PREDICTOR OF PROGRESSION IN ASYMPTOMATIC MULTIPLE MYELOMA. *Haematologica/The Hematology Journal* 94 (Suppl. 4): 85, 2009
47. Rossi F, Petrucci M.T, Guffanti A, Marcheselli L, Rossi D, Callea V, Vincenzo F, De Muro M, Baraldi A, Villani O, Musto P, Bacigalupo A, Gaidano G, Avvisati G, Goldaniga M, **De Paoli L**, Baldini L. PROGNOSTIC SCORING SYSTEMS FOR IGG AND IGA MONOCLONALGAMMOPATHIES OF UNDETERMINED SIGNIFICANCE. *Haematologica/The Hematology Journal* 94 (Suppl. 4): 88, 2009
48. Forconi F, Puma a, **De Paoli L**, Rasi S, Spina V, Gozzetti A, Tassi M, Sozzi E, Cencini E, Raspadori D, Bretoni F, Gattei V, Lauria F, Gaidano G, Rossi D. THE PROGNOSIS OF

- CLINICAL MONOCLONAL B CELL LYMPHOCYTOSIS DIFFERS FROM PROGNOSIS OF RAI 0 CHRONIC LYMPHOCYTIC LEUKAEMIA AND IS RECAPITULATED BY BIOLOGICAL RISK FACTORS. *Haematologica/The Hematology Journal* 94 (Suppl. 4): 187, 2009
49. Rasi S, Fabbri A, Forconi F, Bruscaggin A, Di Rocco A, Fangazio M, Lobetti, Bodoni C, Franceschetti S, **De Paoli L**, Bruna R, Chiappella A, Pogliani EM, Ladetto M, Lauria F, Vitolo U, Hohaus S, Martelli M, Foà R, Gaidano G, Rossi D. A GENETIC VARIANT OF MLH1, A GENE INVOLVED IN DNA MISMATCH REPAIR, IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP. *Haematologica/The Hematology Journal* 95 (Suppl. 3): 26-27, 2010
 50. Deambrogi C, Cresta S, Monti S, **De Paoli L**, Fangazio M, Giardini I, Bernasconi P, Gaidano G, Rossi D. BCL3 TRANSLOCATION IN CLL WITH TYPICAL PHENOTYPE: ASSESSMENT OF FREQUENCY, ASSOCIATION WITH CYTOGENETIC SUBGROUPS AND PROGNOSTIC SIGNIFICANCE. *Haematologica/The Hematology Journal* 95 (Suppl. 3): 90, 2010
 51. Falco P, Benevolo G, Cavallo F, Gaidano G, Carella AM, Guglielmelli T, Rocci A, Rossi D, Grasso M, Mosca Siez ML, Piro E, Lupo B, **De Paoli L**, Boccadoro M, Palumbo A. ORAL REVLMID AND PREDNISONE FOLLOWED BY ORAL REVLMID, MELPHALAN AND PREDNISONE IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS: A MULTICENTER, OPEN LABEL STUDY. *Haematologica/The Hematology Journal* 95 (Suppl. 3): 103-104, 2010
 52. Falco P, Larocca A, Rossi D, Guglielmelli T, Palladino C, **De Paoli L**, Grasso M, Benevolo G, Mosca Siez ML, Piro E, Saraci E, Genuardi M, Carella AM, Gaidano G, Boccadoro M, Plumbo A. MULTICETRER PHASE II STUDY OF LENALIDOMIDE AND PREDNISONE (RP) FOLLOWED BY LENALIDOMIDE, MELPHALAN, PREDNISONE (MPR) IN NEWLY DIAGNOSED ELDERLY UNFIT MULTIPLE MYELOMA PATIENTS. *Haematologica/The Hematology Journal* 96 (Suppl. 3): 48, 2011
 53. Rasi S, Bruscaggin A, Rinaldi A, Cresta S, Fangazio M, **De Paoli L**, Monti S, Gargiulo E, Foà R, Bertoni F, Gaidano G, Rossi D. SALIVA IS A RELIABLE AND PRACTICAL SOURCE OF GERMLINE DNA FOR GENOME-WIDE STUDIES IN CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/The Hematology Journal* 96 (Suppl. 3): 139, 2011
 54. Cerrato C, Brighen S, Cavallo F, Petrucci MT, **De Paoli L**, Siniscalchi A, Genuardi M, Villani O, Offidani M, Magarotto V, Benevolo G, Corradini P, Ruggeri M, Pantani I, Conticello C, Finsinger P, sonneveld P, Boccadoro M, Palumbo A. PHASE II STUDY OF EFFICACY AND SAFETY OF THE COMBINATION CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCD) IN NEWLY DIAGNOSEDMULTIPLE MYELOMA (MM) PATIENTS: PRELIMINARY RESULTS. *Haematologica/The Hematology Journal* 98 (Suppl. 3): 11, 2013
 55. Brighen S, Larocca A, Conticello C, Liberati AM, **De Paoli L**, Falcone AP, Lupparelli G, Buttignol S, Finsinger P, Montefusco V, Offidani M, Benevolo G, Siniscalchi A, Ria R, Zambello R, Carella AM, Pezzatti S, Galli M, Catalano L, Vincelli ID, Grasso M, Guglielmelli T, Cangialosi C, Pescosta N, Rossi G, Musolino C, Musto P, Ciccone G, Boccadoro M, Palumbo A. META-ANALYSIS OF 6383 INDIVIDUAL PATIENT DATA:

SECOND PRIMARY MALIGNANCIES (SPM) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ACCORDING TO LENALIDOMIDE EXPOSURE. *Haematologica/The Hematology Journal* 98 (Suppl. 3): 49-50, 2013

56. Mina R, Larocca A, Montefusco V, Gay F, **De Paoli L**, Crippa C, Cavallo F, Galli M, Marcatti M, Moschetti A, Giuliani N, Guglielmelli T, Rota-Scalabrini D, Caltagirone S, Santagostino A, Baldi I, Spriano M, Boccadoro M, Palumbo A. A PHASE I/II, MULTI-CENTER, OPEN LABEL STUDY OF POMALIDOMIDE, CYCLOPHOSPHAMIDE AND PREDNISONE (PCP) IN PATIENTS WITH MULTIPLE MYELOMA RELAPSED AND/OR REFRACTORY TO LENALIDOMIDE. *Haematologica/The Hematology Journal* 98 (Suppl. 3): 75, 2013
57. Ciardullo C, Rasi S, Spina V, Cerri M, Cresta S, De Paoli L, Guarini A, Rossi D, Foà R, Gaidano G. THE IMPACT OF NEW TECHNOLOGIES ON THE UNDERSTANDING OF CHRONIC LYMPHOCYTIC LEUKEMIA. *Haematologica/The Hematology Journal* 98 (Suppl. 3): 229, 2013